

Nathan P Croft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3414643/publications.pdf>

Version: 2024-02-01

54
papers

2,585
citations

201575

27
h-index

214721

47
g-index

57
all docs

57
docs citations

57
times ranked

3718
citing authors

#	ARTICLE	IF	CITATIONS
1	Anthem: a user customised tool for fast and accurate prediction of binding between peptides and HLA class I molecules. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	37
2	Direct Priming of CD8 ⁺ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation. <i>Journal of Virology</i> , 2021, 95, .	1.5	2
3	IFN γ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation. <i>Frontiers in Immunology</i> , 2021, 12, 645770.	2.2	25
4	Resourcing, annotating, and analysing synthetic peptides of SARS-CoV-2 for immunopeptidomics and other immunological studies. <i>Proteomics</i> , 2021, 21, e2100036.	1.3	7
5	Transcriptional signature in microglia associated with A β plaque phagocytosis. <i>Nature Communications</i> , 2021, 12, 3015.	5.8	142
6	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. <i>Frontiers in Immunology</i> , 2021, 12, 672737.	2.2	8
7	A Novel Humanized Murine Model to Identify Neoantigen-Specific T Cells in CBFA2T3-GLIS2 Positive Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2021, 138, 1708-1708.	0.6	0
8	A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction. <i>Briefings in Bioinformatics</i> , 2020, 21, 1119-1135.	3.2	127
9	T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 49-61.	3.6	91
10	Overlapping Peptides Elicit Distinct CD8 ⁺ T Cell Responses following Influenza A Virus Infection. <i>Journal of Immunology</i> , 2020, 205, 1731-1742.	0.4	9
11	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1322-1334.	1.6	45
12	Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design. <i>Nature Communications</i> , 2020, 11, 6305.	5.8	14
13	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1236-1247.	2.5	25
14	Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system. <i>PLoS Computational Biology</i> , 2020, 16, e1007757.	1.5	60
15	Peptide Presentation to T Cells: Solving the Immunogenic Puzzle. <i>BioEssays</i> , 2020, 42, 1900200.	1.2	3
16	Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses. <i>Nature Communications</i> , 2019, 10, 2846.	5.8	70
17	Response to Comment on "A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands". <i>Science Immunology</i> , 2019, 4, .	5.6	25
18	Most viral peptides displayed by class I MHC on infected cells are immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3112-3117.	3.3	104

#	ARTICLE	IF	CITATIONS
19	In Immunopeptidomics We Need a Sniper Instead of a Shotgun. <i>Proteomics</i> , 2018, 18, e1700464.	1.3	60
20	HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome. <i>Nature Communications</i> , 2018, 9, 4693.	5.8	31
21	A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands. <i>Science Immunology</i> , 2018, 3, .	5.6	142
22	Employing proteomics in the study of antigen presentation: an update. <i>Expert Review of Proteomics</i> , 2018, 15, 637-645.	1.3	23
23	The Use of CRISPR/Cas9 Gene Editing to Confirm Congenic Contaminations in Host-Pathogen Interaction Studies. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 87.	1.8	3
24	Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies. , 2018, 6, 70.		28
25	Characterization of the Antigen Processing Machinery and Endogenous Peptide Presentation of a Bat MHC Class I Molecule. <i>Journal of Immunology</i> , 2016, 196, 4468-4476.	0.4	30
26	Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!. <i>Current Opinion in Immunology</i> , 2016, 40, 88-95.	2.4	30
27	The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. <i>Vaccine</i> , 2016, 34, 5251-5261.	1.7	28
28	Conserved Features in the Structure, Mechanism, and Biogenesis of the Inverse Autotransporter Protein Family. <i>Genome Biology and Evolution</i> , 2016, 8, 1690-1705.	1.1	40
29	Human Leukocyte Antigen (HLA) B27 Allotype-Specific Binding and Candidate Arthritogenic Peptides Revealed through Heuristic Clustering of Data-independent Acquisition Mass Spectrometry (DIA-MS) Data. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1867-1876.	2.5	35
30	A Systems Approach to Understand Antigen Presentation and the Immune Response. <i>Methods in Molecular Biology</i> , 2016, 1394, 189-209.	0.4	27
31	Quantifying epitope presentation using mass spectrometry. <i>Molecular Immunology</i> , 2015, 68, 77-80.	1.0	32
32	Simultaneous Quantification of Viral Antigen Expression Kinetics Using Data-Independent (DIA) Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1361-1372.	2.5	24
33	A comprehensive analysis of peptides presented by HLA-A1. <i>Tissue Antigens</i> , 2015, 85, 492-496.	1.0	27
34	T Cell Cross-Reactivity between a Highly Immunogenic EBV Epitope and a Self-Peptide Naturally Presented by HLA-B*18:01+ Cells. <i>Journal of Immunology</i> , 2015, 194, 4668-4675.	0.4	14
35	Sizing up the key determinants of the CD8+ T cell response. <i>Nature Reviews Immunology</i> , 2015, 15, 705-716.	10.6	111
36	mRNA Structural Constraints on EBNA1 Synthesis Impact on In Vivo Antigen Presentation and Early Priming of CD8+ T Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004423.	2.1	28

#	ARTICLE	IF	CITATIONS
37	A comprehensive analysis of constitutive naturally processed and presented <i><sc>HLA</sc>â€œ*04:01</i> (Cw4)â€œâ€šspecific peptides. Tissue Antigens, 2014, 83, 174-179.	1.0	47
38	Discovery of Novel Disease-specific and Membrane-associated Candidate Markers in a Mouse Model of Multiple Sclerosis. Molecular and Cellular Proteomics, 2014, 13, 679-700.	2.5	10
39	The Cellular Redox Environment Alters Antigen Presentation. Journal of Biological Chemistry, 2014, 289, 27979-27991.	1.6	52
40	Using mass spectrometry to monitor drug induced changes in antigen presentation by the human leukocyte antigen. Clinical and Translational Allergy, 2014, 4, P43.	1.4	0
41	Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes. Journal of Immunology, 2014, 192, 5245-5256.	0.4	9
42	Novel Tumor Derived Peptides in Vaccines. , 2013, , 580-589.		2
43	Kinetics of Antigen Expression and Epitope Presentation during Virus Infection. PLoS Pathogens, 2013, 9, e1003129.	2.1	173
44	HLA Peptide Length Preferences Control CD8+T Cell Responses. Journal of Immunology, 2013, 191, 561-571.	0.4	57
45	Constitutive and Inflammatory Immunopeptidome of Pancreatic Î²-Cells. Diabetes, 2012, 61, 3018-3025.	0.3	67
46	Tracking protein aggregation and mislocalization in cells with flow cytometry. Nature Methods, 2012, 9, 467-470.	9.0	111
47	Peptidomimetics: modifying peptides in the pursuit of better vaccines. Expert Review of Vaccines, 2011, 10, 211-226.	2.0	33
48	Direct quantitation of MHCâ€œbound peptide epitopes by selected reaction monitoring. Proteomics, 2011, 11, 2336-2340.	1.3	66
49	Epitope Discovery and Their Use in Peptide Based Vaccines. Current Pharmaceutical Design, 2010, 16, 3149-3157.	0.9	104
50	Enhancing tumor vaccines: catalyzing MHC class II peptide exchange. Expert Review of Vaccines, 2010, 9, 129-132.	2.0	0
51	Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. PLoS Pathogens, 2009, 5, e1000490.	2.1	80
52	Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen Presentation. Journal of Immunology, 2009, 182, 2313-2324.	0.4	86
53	An HLA-A2-Restricted T-Cell Epitope Mapped to the BNLF2a Immune Evasion Protein of Epstein-Barr Virus That Inhibits TAP. Journal of Virology, 2009, 83, 2783-2788.	1.5	11
54	A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. Journal of Experimental Medicine, 2007, 204, 1863-1873.	4.2	154